Use of oral glucocorticoids and the risk of pulmonary embolism: A population-based case-control study

Chest

Volumn 143, Issue 5, 2013, Pages 1337-1342

  Stuijver, Danka J F ^a,b   Majoor, Christof J ^b   Van Zaane, Bregje ^a,b   Souverein, Patrick C ^c   De Boer, Anthonius ^c   Dekkers, Olaf M ^d   Büller, Harry R ^b   Gerdes, Victor E A ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTIVITAMIN K; BETAMETHASONE; CLOPIDOGREL; CORTICOSTEROID; CORTISONE; DEXAMETHASONE; DIPYRIDAMOLE; GLUCOCORTICOID; HEPARIN DERIVATIVE; HORMONE; HYDROCORTISONE; MEPREDNISONE; ORAL CONTRACEPTIVE AGENT; PREDNISOLONE; PREDNISONE; RESPIRATORY TRACT AGENT; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; ASTHMA; CASE CONTROL STUDY; CHRONIC DRUG ADMINISTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG USE; ENTERITIS; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACY; POPULATION RESEARCH; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYMPTOM; TREATMENT DURATION;

EID: 84877622708     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1446     Document Type: Article

References (30)

1. Hillier SG. Diamonds are forever: the cortisone legacy. J Endocrinol. 2007;195(1):1-6. (Pubitemid 350055993)
2. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105-111. (Pubitemid 30098773)
3. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859-865. (Pubitemid 39005927)
4. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764-770.
5. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92(3):976-981. (Pubitemid 46465672)
6. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40(4):479-484. (Pubitemid 24194645)
7. Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag. 2005;1(4):291-299.
8. Albiger N, Testa RM, Almoto B, et al. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res. 2006;38(6):405-410. (Pubitemid 44047963)
9. de Prada TP, Pozzi AO, Coronado MT, et al. Atherogenesis takes place in cholesterol-fed rabbits when circulating concentrations of endogenous cortisol are increased and inflammation suppressed. Atherosclerosis. 2007;191(2):333-339. (Pubitemid 46420445)
10. Stuijver DJ, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011;96(11):3525-3532.
11. Heaton JH, Nebes VL, O'Dell LG, Morris SM Jr, Gelehrter TD. Glucocorticoid and cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor gene expression in primary cultures of rat hepatocytes. Mol Endocrinol. 1989;3(1):185-192. (Pubitemid 19045690)
12. Huang LQ, Whitworth JA, Chesterman CN. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagul Fibrinolysis. 1995;6(5):438-445.
13. Morange PE, Aubert J, Peiretti F, et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes. 1999;48(4):890-895. (Pubitemid 29153091)
14. van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anticoagulant and fibrinolytic factors. J Thromb Haemost. 2010;8(11):2483-2493.
15. Gottschalk A, Sostman HD, Coleman RE, et al. Ventilation-perfusion scintigraphy in the PIOPED study. Part II. Evaluation of the scintigraphic criteria and interpretations. J Nucl Med. 1993;34(7):1119-1126. (Pubitemid 23191328)
16. Stein PD, Woodard PK, Weg JG, et al; PIOPED II Investigators. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Am J Med. 2006;119(12):1048-1055. (Pubitemid 44826939)
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349. (Pubitemid 351289042)
18. Bertoletti L, Quenet S, Mismetti P, et al. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J. 2012;39(4):862-888.
19. Stein PD, Beemath A, Meyers FA, Olson RE. Pulmonary embolism and deep venous thrombosis in hospitalized adults with chronic obstructive pulmonary disease. J Cardiovasc Med (Hagerstown). 2007;8(4):253-257. (Pubitemid 46586662)
20. Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009;135(3):786-793.
21. Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol. 2006;98(6):793-795. (Pubitemid 44301013)
22. Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol. 2007;21(8):507-511. (Pubitemid 47532873)
23. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(9):2272-2280.
24. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657-663.
25. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605-1621. (Pubitemid 44666739)
26. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-291. (Pubitemid 29439263)
27. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697-706.
28. Niki Y, Matsumoto H, Hakozaki A, Mochizuki T, Momohara S. Rheumatoid arthritis: a risk factor for deep venous thrombosis after total knee arthroplasty? Comparative study with osteoarthritis. J Orthop Sci. 2010;15(1):57-63.
29. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost. 2009;101(1):134-138.
30. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343(8912):1536-1538. (Pubitemid 24180052)